Alan Paris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alan Paris has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Buchamer
Universidad Nacional de La Plata, Facultad de Ciencias Veterinarias, La Plata, Argentina
1 shared publication - Daniel Buldain
Universidad Nacional de La Plata, Facultad de Ciencias Veterinarias, La Plata, Argentina
1 shared publication - Florencia Aliverti
Universidad Nacional de La Plata, Facultad de Ciencias Veterinarias, La Plata, Argentina
1 shared publication - Guillermo Broglia
Laboratorio de Estudios Farmacológicos y Toxicológicos (LEFyT), Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata 1900, Argentina
1 shared publication - Gustavo Castellano
Instituto de Dermatología Veterinaria (IDV), Malvinas Argentinas 1615, Argentina
1 shared publication - Julia di Filippo
Laboratorio de Estudios Farmacológicos y Toxicológicos (LEFyT), Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata 1900, Argentina
1 shared publication
Latest Publications
- Open Access
- 5 January 2026
- Published by Open Exploration Publishing in Exploration of Drug Science
- Vol. 4, 1008138
Novel antimicrobial efficacy on inert surfaces of chlorhexidine-silver nanoparticle veterinary formulation
Aim: This study aimed to establish the in vitro efficacy of chlorhexidine (CHX)-silver nanoparticles (AgNP) based preparation, against Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) in planktonic cultures, biofilms, and on inert stainless-steel surfaces. Methods: The in vitro antimicrobial activity of the CHX-AgNP formulation (Dermosedan MRSA Nano AG®) was evaluated against reference and multidrug-resistant (MDR) strains of S. aureus and P. aeruginosa by determining the minimum inhibitory and bactericidal concentrations (MIC and MBC), as well as the minimum biofilm inhibitory and eradication concentrations (MBIC and MBEC). Also, the residual bactericidal activity on inert stainless-steel surfaces was evaluated. Results: MIC against methicillin-resistant S. aureus (MRSA) and MDR P. aeruginosa (MDR-PA) isolates ranged between 5/2.5–20/10 µg/mL, up to 8,000 times lower than the manufacturer’s recommended concentration, while MBC ranged from 500 to 2,000 times lower. MBIC matched the MBC, while higher concentrations were needed to eradicate preformed biofilms. On stainless-steel surfaces, high antimicrobial activity was observed for both pathogens. No bacterial survival was detected even after 6 hours at 4% CHX + 2% AgNP concentration. The CHX-AgNP combination demonstrated strong antimicrobial and antibiofilm activity against both S. aureus and P. aeruginosa. Conclusions: These results support the potential application of Dermosedan MRSA Nano AG® as a strategy for managing topical resistant infections and for environmental disinfection in both veterinary and clinical settings.
- 5 January 2026
- Published by Open Exploration Publishing in Exploration of Drug Science
- Vol. 4, 1008138
Open AccessNovel antimicrobial efficacy on inert surfaces of chlorhexidine-silver nanoparticle veterinary formulation
Aim: This study aimed to establish the in vitro efficacy of chlorhexidine (CHX)-silver nanoparticles (AgNP) based preparation, against Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) in planktonic cultures, biofilms, and on inert stainless-steel surfaces. Methods: The in vitro antimicrobial activity of the CHX-AgNP formulation (Dermosedan MRSA Nano AG®) was evaluated against reference and multidrug-resistant (MDR) strains of S. aureus and P. aeruginosa by determining the minimum inhibitory and bactericidal concentrations (MIC and MBC), as well as the minimum biofilm inhibitory and eradication concentrations (MBIC and MBEC). Also, the residual bactericidal activity on inert stainless-steel surfaces was evaluated. Results: MIC against methicillin-resistant S. aureus (MRSA) and MDR P. aeruginosa (MDR-PA) isolates ranged between 5/2.5–20/10 µg/mL, up to 8,000 times lower than the manufacturer’s recommended concentration, while MBC ranged from 500 to 2,000 times lower. MBIC matched the MBC, while higher concentrations were needed to eradicate preformed biofilms. On stainless-steel surfaces, high antimicrobial activity was observed for both pathogens. No bacterial survival was detected even after 6 hours at 4% CHX + 2% AgNP concentration. The CHX-AgNP combination demonstrated strong antimicrobial and antibiofilm activity against both S. aureus and P. aeruginosa. Conclusions: These results support the potential application of Dermosedan MRSA Nano AG® as a strategy for managing topical resistant infections and for environmental disinfection in both veterinary and clinical settings.